Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gleave

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Prostate Cancer and Prostatic Diseases|December 24, 2002
Targeting anti-apoptotic genes with antisense oligodeoxy-nucleotides to delay progression to androgen independenceM Gleave
Prostate Cancer and Prostatic Diseases|December 24, 2002
What's hot in the prostate?M Gleave, C Evans
Prostate Cancer and Prostatic Diseases|September 13, 2003
What's hot in the prostate?M Gleave, C P Evans
Prostate Cancer and Prostatic Diseases|December 14, 2004
What's hot in the prostate?M Gleave, C P Evans
Molecular Urology|November 4, 2000
Neoadjuvant hormone therapy: the Canadian trialsL Klotz, M Gleave, S L Goldenberg
BJU International|March 31, 2004
Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumoursA I So, M Bowden, M Gleave
Prostate Cancer and Prostatic Diseases|December 24, 2002
Intermittent androgen suppression for prostate cancer: rationale and clinical experienceM Gleave, S L Goldenberg, N Bruchovsky, et al.
European Urology|December 17, 1998
Intermittent androgen suppression for prostate cancer: rationale and clinical experienceM Gleave, N Bruchovsky, S L Goldenberg, et al.
The Prostate|February 22, 2020
A synopsis of prostate organoid methodologies, applications, and limitationsAnna M Gleave, Xinpei Ci, Dong Lin, et al.
Der Urologe. Ausg. A|September 1, 1995
[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma]N Bruchovsky, S L Goldenberg, P S Rennie, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Prostate Cancer and Prostatic Diseases|December 24, 2002
Targeting anti-apoptotic genes with antisense oligodeoxy-nucleotides to delay progression to androgen independenceM Gleave
Prostate Cancer and Prostatic Diseases|December 24, 2002
What's hot in the prostate?M Gleave, C Evans
Prostate Cancer and Prostatic Diseases|September 13, 2003
What's hot in the prostate?M Gleave, C P Evans
Prostate Cancer and Prostatic Diseases|December 14, 2004
What's hot in the prostate?M Gleave, C P Evans
Molecular Urology|November 4, 2000
Neoadjuvant hormone therapy: the Canadian trialsL Klotz, M Gleave, S L Goldenberg
BJU International|March 31, 2004
Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumoursA I So, M Bowden, M Gleave
Prostate Cancer and Prostatic Diseases|December 24, 2002
Intermittent androgen suppression for prostate cancer: rationale and clinical experienceM Gleave, S L Goldenberg, N Bruchovsky, et al.
European Urology|December 17, 1998
Intermittent androgen suppression for prostate cancer: rationale and clinical experienceM Gleave, N Bruchovsky, S L Goldenberg, et al.
The Prostate|February 22, 2020
A synopsis of prostate organoid methodologies, applications, and limitationsAnna M Gleave, Xinpei Ci, Dong Lin, et al.
Der Urologe. Ausg. A|September 1, 1995
[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma]N Bruchovsky, S L Goldenberg, P S Rennie, et al.
Pageof 4